All News

gout.podagra_0.jpg

Lubricin as a Treatment Target in Gout?

d EurekAlert!

Many Americans think of gout as a disease from a bygone era, akin to rickets or scurvy. The condition commonly afflicted the rich and royal, including American historical figures such as Benjamin Franklin and Thomas Jefferson.

Read Article
cost.price_.drugs_.pills_.jpg

Drug Price Increases Continue in 2023

d Jack Cush, MD

Reuters reports that in 2023, drug makers intend to increase the price of over 350 drugs.

Read Article
GCA,woman

In Giant Cell Arteritis, Hospital Admission Is Bad News

d MedPage Today

One-third of patients admitted with giant cell arteritis (GCA) were rehospitalized within 6 months, largely because of complications potentially related to corticosteroid therapy, researchers found in a retrospective cohort study.

Read Article
OP_0.jpg

ACP Recommends Bisphosphonates as Initial Therapy for Osteoporosis

d EurekAlert!

The American College of Physicians (ACP) has issued an update of its guideline with clinical recommendations for treatments of primary osteoporosis and low bone mass in adults.

Read Article
Dr. Kristi Kuhn & Univ of Colorado researchers have linked RA risk with the gut bacterium Subdoligranulum didolesgii. This could be pathogenically important and supports their "Mucosal origins hypothesis" to RA risk https://t.co/xDyejVR8MW https://t.co/M663ziXOcT https://t.co/y7zpukZah5

Links:

Dr. John Cush RheumNow ( View Tweet)

Differential Dx of hyperferritinemia (≥500 μg/) in critically ill ICU pts includes: sepsis, liver disease/failure, hematological malignancy, HLH. Single center study of 2583 patients https://t.co/yuqJcyLIP5 https://t.co/vHLqJGP4mv

Links:

Dr. John Cush RheumNow ( View Tweet)
40 yoF with Chronic cough and dyspnea - Lung Fibrosis in Systemic Sclerosis https://t.co/4NYa0l9Dci https://t.co/XTDLKPtrkH

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums manage #RA. But patients have to manage RA and their lives - I wish we could provide better guidance to our patients about Life with RA. Heres one patient from Wash, DC who accomplished SO MUCH in 2022 and she has RA! @hirokonishimura https://t.co/QStFGZLsTR https://t.co/Q7GoYQYvwx

Links:

Dr. John Cush RheumNow ( View Tweet)
Gilead Sciences and EVOQ Therapeutics have a new 2023 partnership to develop immunotherapies for RA & SLE - using NanoDisc technology with lymph-targeted delivery of disease-specific-antigens. Gilead has IRAK4 inhibitor, GS-5718in Phase I https://t.co/kanUXUhMSm https://t.co/ZaDH1ueWrl

Links:

Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine significantly lowers Alzheimer’s and dementia risk. Study of g 109,124 #RA pts starting HCQ or MTX. showed an 8-16% lower risk. https://t.co/q516bZPOq5 https://t.co/2xdOa8pVAv

Links:

Dr. John Cush RheumNow ( View Tweet)
Humira biosimilars became available in EU 10/18; and will soon be available in the USA w/ Amjevita (Amgen) available Jan 2023 & 6 others (Pfizer, BI, Samsung, Coherus, Sandoz, Biocon) after July 2023. https://t.co/m8cdJgM7UC

Links:

Dr. John Cush RheumNow ( View Tweet)

Retrospective Claims analysis 1663 #SLE pts shows pts w/ lupus nephritis (LN, 2916) had higher Charlson Comorbidity scores ≥4 (72 vs 14%) & inpatient (41 vs 17%). LUPUS FLARES were more (61 vs 54%), more severe (11 vs 5%) & twice the cost https://t.co/tXI7SSalaV https://t.co/z0SorOQilb

Links:

Dr. John Cush RheumNow ( View Tweet)
Medical (AKA surgical) masks are not inferior to N95 fitted masks. A study of 1009 medical workers in 4 countries caring for COVID+ infected patients shows equal rate of PCR+ COVID tests (10.5% vs 9.3% +) (HR 1.14 [95% CI, 0.77 to 1.69]) https://t.co/wTuLHcOxlO https://t.co/gjqfLOU7JW

Links:

Dr. John Cush RheumNow ( View Tweet)
2002-2019 Canadian study of Rheumatology care: access has improved but problems exist, esp w/ DMARD use. In 112,494 new RA pts, 84% saw Rheum <1yrs w/ 43% increase by 2019. Suboptimal DMARD use in elderly improved 55 to 69% https://t.co/tpv514P0GP https://t.co/AIRuf7u60d

Links:

Dr. John Cush RheumNow ( View Tweet)
Do not take antacids or PPI with mycophenolate. Magnesium & aluminium hydroxide antacids (Maalox) will lower MMF Cmax 33% & AUC 17% if given simultaneously. PPI also lowers AUC by ~33% https://t.co/D0eQWcON2J https://t.co/rK77lCmbVv https://t.co/5X0e6DBxAh https://t.co/ZpJtc8SdcG

Links:

Dr. John Cush RheumNow ( View Tweet)
COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at wk 16 (PASDAS 3·1 vs 3·7; p=0·025). Combo group had more N/V (44% v 28%), ^ALT (31% vs 18%). https://t.co/22DhyJUeuo

Links:

Dr. John Cush RheumNow ( View Tweet)

Welcome, January 2023 ❄️. It's the 50th year of the publication @jrheum ✨🎊! View the full issue online 👉 https://t.co/GsZdjMZF1T #rheumatoidarthritis #spondyloarthritis #psoriaticarthritis #lupus #vasculitis #pediatric #gout #rheumatology #50thyearofpublication #jrheum50 https://t.co/keUVRVD8vW

Links:

The Journal of Rheumatology jrheum ( View Tweet)
COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at wk 16 (PASDAS 3·1 vs 3·7; p=0·025). Combo group had more N/V (44% v 28%), ^ALT (31% vs 18%). https://t.co/D2GYjbR7y2 #BestOf2022

Links:

Dr. John Cush RheumNow ( View Tweet)

INBUILD Study of 170 pts with autoimmune related ILD showed nintedanib signifi. slowed the rate of FVC decline in FVC decline over 52 wks (NIN -75.9 mL/yr vs PBO -178.6 mL/yr). AE's (mostly diarrhea) leading to D/C was NIN 17.1% vs PBO 10.2% https://t.co/CmbF5NQMfJ #BestOf2022

Links:

Dr. John Cush RheumNow ( View Tweet)

608 EARLY RA pts in BARFOT study had Xrays over time. 24% did not show Erosions after 8 yrs. Pt w/ NO Erosions were younger, younger, w Less ACR criteria, & seronegative at Dx. They had more TJC, less SJC, lower ESR, less DMARDs & pred Rx. https://t.co/5jYNd7bwE3 https://t.co/z3Y0TPJTwd

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×